Composition for treating chloasma, preparation method and application thereof

Abstract

The present invention provides a composition for treating chloasma, its preparation method, and use. The composition comprises peony bark, lily, rose, rose, peach kernel, astragalus root, white moss bark, white ampelopsis root, white bletilla striata root, white poria, white peony root, and white chrysanthemum. This composition can address the problem of slow efficacy and weak effects of existing drugs for treating chloasma, and is applicable to the field of traditional Chinese medicine preparation technology.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine preparations, and in particular to a composition for treating chloasma, a preparation method thereof, and an application thereof. Background Art

[0002] Melasma, which affects the face, can affect appearance and cause significant mental stress for women. With today's ever-accelerating pace of life, melasma sufferers often experience chronic fatigue, insufficient rest, and poor emotional well-being. Chloasma can also be triggered by long-term depression and neurasthenia, and psychological factors should not be ignored.

[0003] The Western medical pathological mechanisms of melasma include melanocyte activation and aggregation, mast cell proliferation and solar elastosis, vascular proliferation, and basement membrane disruption. Increased skin pigmentation may be related to impaired barrier function. Western medical treatments primarily include medications, chemical peels, and lasers, often combining two or more. However, both oral and topical Western medicines have side effects. Lowering the dosage to minimize these side effects can reduce efficacy and require longer treatment sessions.

[0004] In Traditional Chinese Medicine (TCM), the pathogenesis of melasma is liver depression and qi stagnation, qi stagnation and blood stasis, spleen and stomach deficiency, liver and kidney deficiency, poor circulation of qi, blood, and body fluids, and endocrine imbalances, which manifest on the face. Treatment principles emphasize soothing the liver, strengthening the spleen, and tonifying the kidneys, regulating qi, promoting blood circulation, and removing blood stasis. Treatment methods should integrate internal and external treatments, addressing both the symptoms and the root cause. External TCM treatments include Chinese herbal masks, acupuncture, cupping, and scraping. However, these treatments often have a slow effect. Therefore, existing medications and methods for treating melasma have yet to achieve a clinically effective and side-effect-free treatment. Summary of the Invention

[0005] The main purpose of the present invention is to provide a composition for treating chloasma, a preparation method and application thereof, so as to solve the problem that the drugs for treating chloasma in the prior art have slow efficacy and weak effect.

[0006] In order to achieve the above-mentioned object, according to the first aspect of the present invention, a composition for treating chloasma is provided, which comprises peony bark, lily, rose, rose, peach kernel, astragalus, white moss bark, white ampelopsis, white striata, white bombyx batryticatus, white poria, white peony root and white chrysanthemum.

[0007] Further, the composition includes 10-20 parts of peony bark, 10-20 parts of lily, 10-20 parts of rose, 10-20 parts of rose, 10-20 parts of peach kernel, 10-20 parts of astragalus, 10-20 parts of white peony root, 10-20 parts of white striata, 10-20 parts of white silkworm, 10-20 parts of white poria, 10-20 parts of white peony root, 10-20 parts of white chrysanthemum and 10-20 parts of white moss peel; preferably, the composition includes equal parts by weight of peony bark, lily, rose, rose, peach kernel, astragalus, white peony root, white peony root, white silkworm, white poria, white peony root, white chrysanthemum and white moss peel; preferably, the composition also includes auxiliary materials; preferably, the auxiliary materials include one or more of egg white, honey or milk; preferably, the cause of chloasma includes liver depression and qi stagnation.

[0008] According to a second aspect of the present invention, a method for preparing a composition for treating chloasma is provided, which comprises preparing a composition for treating chloasma using rose, rose, peony bark, lily, peach kernel, astragalus, white ampelopsis, white striata, white bombyx batryticatus, white poria, white peony root, white chrysanthemum and white moss peel.

[0009] Furthermore, the preparation method includes respectively crushing rose, rose, peony bark, lily, peach kernel, astragalus, white ampel, white striata, white silkworm, white poria, white peony root, white chrysanthemum and white moss bark to obtain corresponding raw material powders; sieving and mixing the multiple raw material powders to obtain raw material powders; mixing the raw material powders with auxiliary materials to obtain a composition for treating chloasma; preferably, the cause of chloasma includes liver depression and qi stagnation.

[0010] Furthermore, the auxiliary materials include one or more of egg white, honey or milk.

[0011] Furthermore, sieving is to pass the various raw material powders through a 150-200 mesh sieve; preferably, sieving is to pass the various raw material powders through a 200 mesh sieve.

[0012] Furthermore, the preparation method further comprises: mixing the raw material powder with the auxiliary materials and water to obtain a composition for treating chloasma; preferably, the temperature of the water is 40-60°C.

[0013] Furthermore, the composition comprises, by mass, 10-20 parts of rose, 10-20 parts of rose, 10-20 parts of peony bark, 10-20 parts of lily, 10-20 parts of peach kernel, 10-20 parts of astragalus, 10-20 parts of white amphibians, 10-20 parts of white striata, 10-20 parts of white silkworm, 10-20 parts of white poria, 10-20 parts of white peony, 10-20 parts of white chrysanthemum and 10-20 parts of white moss peel; preferably, the composition comprises equal parts of peony bark, lily, rose, rose, peach kernel, astragalus, white amphibians, white striata, white silkworm, white poria, white peony, white chrysanthemum and white moss peel.

[0014] According to a third aspect of the present invention, a preparation for treating chloasma is provided, which comprises a composition for treating chloasma and optional ingredients, wherein the optional ingredients include excipients and / or carriers.

[0015] Furthermore, the preparation is in the form of an external preparation; external preparations include liniments, ointments, sprays, patches or lotions; preferably, the cause of chloasma includes liver depression and qi stagnation.

[0016] By applying the technical solution of the present invention, a composition for treating chloasma containing rose, rose, peony bark, lily, rose, rose, peach kernel, astragalus, white ampelopsis, white striata, bombyx batryticatus, white poria, white peony root, white chrysanthemum and white moss peel is utilized. This composition can accelerate the treatment process when treating chloasma, thus solving the problem of slow efficacy of products using traditional Chinese medicine treatment methods in the prior art for treating chloasma. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The accompanying drawings, which constitute part of this application, are intended to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are intended to explain the present invention and do not constitute an undue limitation of the present invention. In the accompanying drawings:

[0018] Figure 1 A schematic diagram of a linear mixed effects model for comparing MASI scores among the experimental group, control group 1, and control group 2 according to Example 1 of the present invention is shown.

[0019] Figure 2 The schematic diagram shows the effect of patient A before and after treatment according to Example 2 of the present invention; wherein, Figure 2 Figure a is a diagram of the facial condition of patient A before treatment. Figure 2 Middle b is a schematic diagram of the facial condition of patient A 6 weeks after treatment.

[0020] Figure 3 The schematic diagram shows the effect of patient B before and after treatment according to Example 3 of the present invention; wherein, Figure 3 Figure a is a diagram of the facial condition of patient B before treatment. Figure 3 Middle b is a schematic diagram of the facial condition of patient B 6 weeks after treatment. DETAILED DESCRIPTION

[0021] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present invention will be described in detail below with reference to the embodiments.

[0022] As mentioned in the background, chloasma is often treated with combined therapies. However, both oral and topical Western medicines have side effects. Reducing the dosage to minimize these side effects can lead to decreased efficacy and longer treatment courses. However, using existing traditional Chinese medicines often results in slower efficacy. Therefore, in this application, the inventors attempted to develop a composition for treating chloasma and proposed a series of protection schemes.

[0023] In a first typical embodiment of the present application, a composition for treating chloasma is provided, which comprises rose, rose, peony bark, lily, peach kernel, astragalus, white ampelopsis, white striata, white bombyx batryticatus, white poria, white peony root, white chrysanthemum and white moss peel.

[0024] Because the cause of chloasma includes because the patient has an irregular diet and work and rest, causes the formation of toxic heat in the body, thus causes endocrine disorders, thus causes chloasma to occur. Therefore, in the composition for treating chloasma in the present application, in addition to increasing the composition of promoting blood circulation and removing blood stasis, the composition that can play the effect of cooling blood and nourishing yin is also added simultaneously, both can alleviate the pigmentation of chloasma, can also alleviate the problems such as skin sensitivity and itching accompanied by chloasma. The composition for treating chloasma in the present application, with promoting blood circulation, nourishing yin, moistening dryness, nourishing skin as leading, including Flos Rosae Chinensis, Semen Persicae, Cortex Moutan, Lily, Flos Rosae, Radix Astragali and Cortex Dictamni Composition, and on this basis, increase the composition of Radix Bletillae, Rhizoma Bletillae, Bletillae Bastiae, White Poria, White Peony Root and Flos Chrysanthemi to enhance the effect of whitening. The composition for treating chloasma in the present application, while promoting blood circulation and removing freckles, can also nourish yin and moisten dryness, whiten and remove freckles and nourish skin, and further repair skin barrier, and high safety, stable efficacy.

[0025] The ancient formula Qibai San or Qizibai, first recorded in the Yuan Dynasty's Imperial Pharmacy Prescriptions and Taiping Shenghui Prescriptions, includes ingredients such as Angelica dahurica, Bletilla striata, Atractylodes macrocephala, White aconite root, White Poria cocos, Chicken egg white, and Asarum, or alternatively, Atractylodes macrocephala, Angelica dahurica, Bletilla striata, Bletilla striata, White Poria cocos, White Poria cocos, and Bombyx batryticatus, with varying formulations. While these formulas are commonly used for freckle removal and whitening, due to the complex causes of melasma and the wide range of body constitutions experienced by patients, these ancient formulas are ineffective in achieving a radical cure for melasma in modern patients, failing to address the underlying cause and resulting in slow efficacy. The present application adaptively adjusts the composition of the "Seven Whites" and selects seven medicinal materials including white ampelopsis, white striata, white silkworm, white poria, white peony root, white chrysanthemum and white moss bark, and then adds rose, peach kernel, peony bark, lily, rose and astragalus to the above composition to exert the synergistic effect of multiple Chinese medicinal ingredients to prepare the composition for treating chloasma in the present application.

[0026] The composition for treating chloasma in the present application can also invigorate blood circulation and nourish yin, moisten dryness and cool blood from the inside, and can also whiten and remove spots from the outside, achieving the effect of treating both the symptoms and the root cause. However, when the ancient formula Qibai San is used to treat chloasma, it cannot achieve the effect of treating both the symptoms and the root cause. Compared with the ancient formula Qibai San, the formula of the present application is faster in effect, has a shorter course of treatment, is more suitable for the physique of modern people, and has a better effect in treating chloasma.

[0027] In the composition for treating chloasma of the present application, rose and Chinese rose have the effect of promoting blood circulation and removing freckles; peach kernel has the effect of promoting blood circulation and moisturizing the skin; peony bark and lily have the effect of promoting blood circulation, reducing inflammation, nourishing the skin and moisturizing the skin; astragalus has the effect of protecting the skin barrier, and white moss peel has the effect of removing freckles and relieving itching; white ampelopsis, white striata, white silkworm, white poria, white peony root and white chrysanthemum have the effect of enhancing whitening effect, and white chrysanthemum and white moss peel also have the effect of relieving fever; each component works synergistically to achieve the effects of promoting blood circulation, nourishing yin, moisturizing dryness, whitening and removing freckles.

[0028] In a preferred embodiment, the composition comprises, by mass, 10-20 parts of peony bark, 10-20 parts of lily, 10-20 parts of rose, 10-20 parts of rose, 10-20 parts of peach kernel, 10-20 parts of astragalus, 10-20 parts of white peony root, 10-20 parts of white striata, 10-20 parts of white bombyx batryticatus, 10-20 parts of white tuckahoe, 10-20 parts of white peony root, 10-20 parts of white chrysanthemum and 10-20 parts of white moss peel; preferably, the composition comprises equal parts of peony bark, lily, rose, rose, peach kernel, astragalus, white peony root, white peony root, white striata, white bombyx batryticatus, white tuckahoe, white peony root, white chrysanthemum and white moss peel; preferably, the composition further comprises an auxiliary material; preferably, the auxiliary material comprises one or more of egg white, honey or milk; preferably, the cause of chloasma comprises liver depression and qi stagnation.

[0029] In the present application, in addition to egg white, honey and milk, the excipients also include one or more of microcrystalline cellulose, pregelatinized starch, magnesium stearate, corn starch or wheat starch. The present application has no particular restrictions on the source of the excipients, and any of the above excipients known to those skilled in the art can be used.

[0030] In a second typical embodiment of the present application, a method for preparing a composition for treating chloasma is provided, wherein the composition for treating chloasma is prepared using peony bark, lily, rose, rose, peach kernel, astragalus, white ampelopsis, white striata, white bombyx batryticatus, white poria, white peony root, white chrysanthemum and white moss peel.

[0031] In a preferred embodiment, the preparation method comprises respectively crushing peony bark, lily, rose, rose, peach kernel, astragalus, white ampelopsis, white striata, white silkworm, white poria, white peony root, white chrysanthemum pollen and white moss peel to obtain corresponding raw material powders; sieving and mixing the multiple raw material powders to obtain raw material powders; mixing the raw material powders with auxiliary materials to obtain a composition for treating chloasma; preferably, the cause of chloasma includes liver depression and qi stagnation.

[0032] In a preferred embodiment, the auxiliary material includes one or more of egg white, honey or milk.

[0033] In a preferred embodiment, the sieving is to pass the various raw material powders through a 150-200 mesh sieve, including but not limited to a 150, 160, 170, 180, 190 or 200 mesh sieve; preferably, the sieving is to pass the various raw material powders through a 200 mesh sieve.

[0034] In a preferred embodiment, the above preparation method further includes mixing the raw powder with excipients and water to obtain a composition for treating chloasma; the temperature of the water is 40-60°C, including but not limited to 40°C, 45°C, 50°C, 55°C or 60°C.

[0035] In a preferred embodiment, the composition for treating chloasma comprises, by mass, 10-20 parts of peony bark, 10-20 parts of lily, 10-20 parts of rose, 10-20 parts of rose, 10-20 parts of peach kernel, 10-20 parts of astragalus, 10-20 parts of white amphibians, 10-20 parts of white striata, 10-20 parts of white bombyx batryticatus, 10-20 parts of white tuckahoe, 10-20 parts of white peony root, 10-20 parts of white chrysanthemum and 10-20 parts of white moss peel; preferably, the composition comprises equal parts of peony bark, lily, rose, rose, peach kernel, astragalus, white amphibians, white striata, white bombyx batryticatus, white tuckahoe, white peony root, white chrysanthemum and white moss peel.

[0036] In a third typical embodiment of the present application, a preparation for treating chloasma is provided, which comprises any of the above-mentioned compositions for treating chloasma and optional ingredients, wherein the optional ingredients include excipients and / or carriers.

[0037] In a preferred embodiment, the preparation is in the form of an external preparation; external preparations include liniments, ointments, sprays, patches or lotions; preferably, the cause of chloasma includes liver depression and qi stagnation.

[0038] By using the above-mentioned excipients and / or carriers, a preparation for external use can be prepared based on the above-mentioned composition, which can be applied directly to the affected area on the face and has a faster therapeutic effect than oral medication.

[0039] The beneficial effects of the present application will be further explained in detail below with reference to specific embodiments.

[0040] Example 1

[0041] 1. Experimental group: the composition for treating chloasma in the present application.

[0042] Control group 1: tretinoin cream;

[0043] Control group 2: Qibaisan.

[0044] A composition for treating chloasma is prepared by crushing 10g of rose flower, 10g of rose chinensis flower, 10g of peony bark, 10g of lily, 10g of peach kernel, 10g of astragalus root, 10g of white ampelopsis root, 10g of white striata root, 10g of white bombyx batryticatus, 10g of white poria, 10g of white peony root, 10g of white chrysanthemum flower, and 10g of white moss bark into corresponding raw material powders; passing the various raw material powders through a 200-mesh sieve and uniformly mixing them to obtain a raw material powder; and uniformly mixing 3g of the raw material powder with 20ml of milk to form a paste to obtain a composition for treating chloasma.

[0045] Preparation of Qibai Powder: Grind 10g of Bletilla striata, 10g of Bletilla striata, 10g of Bombyx batryticatus, 10g of Poria cocos, 10g of White Peony Root, 10g of Atractylodes macrocephala, and 10g of Angelica dahurica into corresponding raw material powders, pass the various raw material powders through a 200-mesh sieve, and mix them evenly to obtain Qibai raw material powder; mix 3g of Qibai raw material powder with 20mL of milk evenly to form a paste to obtain Qibai Powder.

[0046] Usage: Experimental group: patients applied the composition for treating chloasma externally on the chloasma, 3 times / week, 15 minutes / time.

[0047] Control group 1: Patients washed their faces with warm water every night before bed and then evenly applied tretinoin ointment (manufactured by Chongqing Huabang Pharmaceutical Co., Ltd.) to the melasma areas. Treatment continued for 6 weeks.

[0048] Control group 2: Patients applied Qibaisan externally on the melasma, 3 times / week, 15 minutes / time.

[0049] Observation time: 6 weeks of treatment, with records recorded once a week during treatment, and 4 weeks of follow-up, with records recorded once a week.

[0050] 2. Inclusion criteria for patients in the experimental and control groups

[0051] 2.2 Inclusion criteria:

[0052] ①Meet the diagnostic criteria for melasma;

[0053] ②Age 25-50 years old;

[0054] ③ Traditional Chinese medicine diagnosis is consistent with liver depression and qi stagnation syndrome;

[0055] ④ Those who have signed the informed consent form;

[0056] 2.3 Exclusion criteria (any one of the following applies):

[0057] ① Pigmentation caused by other diseases;

[0058] ② Patients who are currently receiving other treatments or have received other treatments within the past month;

[0059] ③ Pregnant and lactating women;

[0060] ④ Those who have taken drugs that affect endocrine function in the past six months, or those with menopause, diabetes, chronic liver and kidney dysfunction, autoimmune diseases, or serious primary diseases of the heart, liver, kidney, and hematopoietic systems, or mental illness;

[0061] ⑤ Known allergy to the test drug (single Chinese medicine);

[0062] ⑥Age less than 25 and greater than 50.

[0063] 2.4 Criteria for suspension and withdrawal of cases (any of the following):

[0064] ① Unable to persist in treatment;

[0065] ②Adverse reactions such as drug allergy or serious complications occur during clinical trials;

[0066] ③ Those who do not follow this treatment plan or interrupt this treatment plan.

[0067] 3. Subjective evaluation and clinical treatment effectiveness

[0068] 3.1 By observing the changes in the area of ​​pigmentation in all patients before and after treatment, the effects of the two treatment methods were compared.

[0069] Significantly effective: The area of ​​the spots has subsided by at least 90% and the color of the yellow spots has faded by naked eye observation;

[0070] Effective: The area of ​​the spots disappears by ≥60% and <90% by naked eye observation, and the color of the macular part disappears;

[0071] Improvement: The area of ​​the spots subsides by ≥40% and <60%, and the color becomes slightly lighter;

[0072] Ineffective: The area of ​​the spots subsided by less than 40% and the color of the yellow spots did not change when observed with the naked eye.

[0073] Total effective rate = (number of cases with marked effect + effective effect + improved effect) / total number of cases × 100%.

[0074] 3.2 Melasma Area Severity Index (MASI) Scoring: Melasma is quantified based on its area, color depth, and color uniformity. MASI = forehead [0.3A(D+H)] + right cheek [0.3A(D+H)] + left cheek [0.3A(D+H)] + chin [0.1A(D+H)].

[0075] A is the area of ​​chloasma involvement: 0 points (normal), 1 point (<10%), 2 points (10%-29%), 3 points (30%-49%), 4 points (50%-69%), 5 points (70%-89%), 6 points (90%-100%);

[0076] D is the degree of color deepening: 0 is no deepening, 1 is slight deepening, 2 is general deepening, 3 is obvious deepening, and 4 is severe deepening);

[0077] H represents pigment uniformity: 0 indicates extremely uneven pigmentation, 1 indicates slightly uniform pigmentation, 2 indicates moderately uniform pigmentation, 3 indicates markedly uniform pigmentation, and 4 indicates completely uniform pigmentation. The total score ranges from 0 to 48, with higher scores indicating more severe melasma.

[0078] MASI reduction rate = (pre-treatment score - post-treatment score) / pre-treatment score × 100%. Completed (Cure) is defined as a MASI reduction of ≥90%; markedly effective (50%-89%); effective (10%-49%); and ineffective (≤10%). Both scores were evaluated by two dermatologists who were not involved in the study, reviewing the photographs, and the average of these scores was calculated.

[0079] 3.3 Patient satisfaction evaluation: Investigate patients’ satisfaction with the efficacy, divided into:

[0080] Very satisfied (improvement ≥75%);

[0081] Satisfied (50% to 75% improvement);

[0082] Fair (improvement of 25% to 50%, excluding the endpoint of 50%);

[0083] Unsatisfactory (improvement ≤ 25%, excluding the endpoint value of 25%), the satisfaction rate was calculated;

[0084] Satisfaction rate = (number of very satisfied + satisfied + average) cases / total number of cases × 100%.

[0085] 3.4 Adverse Reactions

[0086] Adverse reactions include itching, burning, and erythema.

[0087] 4. Statistical analysis

[0088] SPSS 22.0 statistical software was used for data analysis. Continuous data were expressed as mean (×) ± standard deviation (s); t-test was used for comparison of continuous data; ×2 test was used for comparison of categorical data; the test level was α = 0.05.

[0089] 5. Results

[0090] 5.1 Subjective Evaluation

[0091] The subjective evaluation efficacy rates of the three melasma groups were 100.0%, 90.0%, and 93.3%, respectively, for the experimental group, control group 1, and control group 2. There were statistically significant differences between the experimental group and control groups 1 and 2 (P < 0.05). The results are shown in Tables 1 and 2, respectively. The subjective evaluation of efficacy in the experimental group was superior to that in control groups 1 and 2.

[0092] Table 1

[0093]

[0094] Table 2

[0095]

[0096] 5.2 Comparison of MASI scores

[0097] Before treatment, there was no statistical difference between the experimental group and the control group, but there was a significant difference between the two groups after treatment. The experimental group and the control group were compared using a paired t-test, and the two groups were compared using an independent sample t-test before and after treatment. The results of the patients before and after treatment after one cycle of treatment are shown in Table 3; the MASI scores of the patients at week 0, week 2, week 4, and week 6 of treatment are shown in Table 4. The linear mixed effect model of the experimental group, control group 1, and control group 2 is shown in Table 4. Figure 1 shown.

[0098] Table 3

[0099]

[0100]

[0101] Significance: Control group 1 vs experimental group: P < 0.05, Control group 2 vs experimental group: P < 0.001.

[0102] Table 4

[0103] Group Week 0 Week 2 Week 4 Week 6 Control group 1 22.29±4.78 21.78±4.87 12.53±4.70 7.05±2.33 Control group 2 22.74±4.50 20.84±4.62 13.71±4.39 8.37±3.41 Experimental group 23.17±6.69 17.30±6.40 10.51±4.99 5.27±3.03

[0104] The MASI decrease rate in the experimental group was better than that in the control group 1 and the control group 2. The comparison of the MASI decrease rate between the experimental group and the control group 1 is shown in Table 5, and the comparison of the MASI decrease rate between the experimental group and the control group 2 is shown in Table 6.

[0105] Table 5

[0106]

[0107] Table 6

[0108]

[0109] 5.3 Satisfaction Evaluation

[0110] The overall satisfaction level of the experimental group was significantly better than that of control group 1 and control group 2. The comparison of the satisfaction levels between the experimental group and control group 1 is shown in Table 7, and the comparison of the satisfaction levels between the experimental group and control group 2 is shown in Table 8.

[0111] Table 7

[0112]

[0113] Table 8

[0114]

[0115] In summary, there were no significant differences between the three treatment groups before treatment. After treatment, the freckle removal effects of the experimental groups were superior to those of control groups 1 and 2. Furthermore, the composition for treating melasma in the experimental groups took effect more quickly, and patient satisfaction with treatment was superior to that of control groups 1 and 2.

[0116] Example 2

[0117] Patient A in the experimental group of Example 1 complained of skin pigmentation on both cheeks for more than 2 years. Two years ago, the patient discovered brown patches on both cheeks, with a dark yellowish complexion that gradually worsened. The patient was given the composition for treating chloasma in Example 1 for daily external application. One week later, at the second visit, the patient's skin patches on both cheeks and around the eyes became lighter in color, and the complexion became radiant. After the third visit, the facial pigmentation was significantly alleviated, and the skin tone was even. The results of patient A before treatment and after 6 weeks of treatment are shown in the figure below. Figure 2 As shown, Figure 2 Figure a is a diagram of the facial condition of patient A before treatment. Figure 2 Middle b is a schematic diagram of the facial condition of patient A 6 weeks after treatment.

[0118] Example 3

[0119] Patient B in the experimental group of Example 1 complained of skin discoloration on the cheeks and the corners of the eyes for more than a year. One year ago, the patient discovered skin discoloration on the cheeks and the corners of the eyes, decreased menstrual volume, irritability, normal bowel movements, good appetite and sleep, red tongue with thin fur, and deep and fine pulse. The patient was given the composition for treating chloasma in Example 1 at the first visit. At the second visit one week later, the patient's skin was shiny and the patches were lighter than before. The external application was continued, and at the third visit, the patient's skin was even-toned and shiny, the cheek spots were lighter than at the second visit, the spots at the corners of the eyes were significantly lighter, and the skin color was even-toned. The results of patient B before treatment and 6 weeks after treatment are as follows. Figure 3 As shown, Figure 3 Figure a is a diagram of the facial condition of patient A before treatment. Figure 3 Middle b is a schematic diagram of the facial condition of patient A 6 weeks after treatment.

[0120] From the above description, it can be seen that the above embodiments of the present invention achieve the following technical effects:

[0121] The composition for treating melasma disclosed herein can invigorate blood circulation, whiten skin, and nourish yin and moisturize the skin while treating melasma. It is more effective and has a shorter treatment course than existing traditional Chinese medicine treatments and the ancient formula Qibaisan, with significant results seen in approximately 4 to 7 days. Furthermore, the composition for treating melasma disclosed herein has a simple preparation method, high safety of its ingredients, low treatment cost, and stable efficacy, making it suitable for widespread use in the treatment of melasma.

[0122] The foregoing description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Those skilled in the art will readily appreciate that various modifications and variations of the present invention are possible. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention are intended to be within the scope of protection of the present invention.

Claims

1. A composition for treating chloasma, characterized in that: The composition is composed of peony bark, lily, rose, rose, peach kernel, astragalus, white moss bark, white ampelopsis, white striata, white bombyx batryticatus, white tuckahoe, white peony root and white chrysanthemum; The composition consists of 10-20 parts of peony bark, 10-20 parts of lily, 10-20 parts of rose, 10-20 parts of rose, 10-20 parts of peach kernel, 10-20 parts of astragalus, 10-20 parts of white ampelopsis, 10-20 parts of white striata, 10-20 parts of white bombyx batryticatus, 10-20 parts of white tuckahoe, 10-20 parts of white peony root, 10-20 parts of white chrysanthemum and 10-20 parts of white moss peel by mass.

2. The composition according to claim 1, characterized in that The composition consists of equal parts by weight of peony bark, lily, rose, rose, peach kernel, astragalus, white ampelopsis, bletilla striata, white bombyx batryticatus, white tuckahoe, white peony root, white chrysanthemum and white moss bark.

3. A method for preparing a preparation for treating chloasma, characterized in that: The preparation method comprises: The preparation for treating chloasma is prepared by using rose, rose, peony bark, lily, peach kernel, astragalus, white ampel, white striata, white bombyx batryticatus, white tuckahoe, white peony root, white chrysanthemum and white moss peel; The preparation method comprises the steps of respectively crushing rose, rose, peony bark, lily, peach kernel, astragalus, white ampel, bletilla striata, white bombyx batryticatus, white tuckahoe, white peony root, white chrysanthemum and white moss bark to obtain corresponding raw material powders; sieving and mixing the plurality of raw material powders to obtain a raw material powder; mixing the raw material powder with auxiliary materials to obtain the preparation for treating chloasma; The preparation consists of 10-20 parts of rose, 10-20 parts of rose, 10-20 parts of peony bark, 10-20 parts of lily, 10-20 parts of peach kernel, 10-20 parts of astragalus, 10-20 parts of white ampelopsis, 10-20 parts of white striata, 10-20 parts of white bombyx batryticatus, 10-20 parts of white poria, 10-20 parts of white peony root, 10-20 parts of white chrysanthemum and 10-20 parts of white moss peel by mass.

4. The preparation method according to claim 3, characterized in that The auxiliary material is egg white, honey or milk.

5. The preparation method according to claim 3, characterized in that The sieving is to sieve the various raw material powders through a 150-200 mesh sieve respectively.

6. The preparation method according to claim 3, characterized in that The raw material powder is composed of equal parts by weight of peony bark, lily, rose, rose, peach kernel, astragalus, white ampelopsis, bletilla striata, white bombyx batryticatus, white tuckahoe, white peony root, white chrysanthemum and white moss bark.

7. A preparation for treating chloasma, characterized in that: The preparation is made from the composition for treating chloasma according to any one of claims 1 to 2 and auxiliary materials.

8. The preparation according to claim 7, characterized in that The dosage form of the preparation is an external preparation.

9. The preparation according to claim 8, characterized in that The external preparation is a liniment, an ointment, a spray, a patch or a lotion.

Images